Peter Chu

Peter is a scientist turned entrepreneur who has held positions at small, medium, and large biotech companies during his 20-year career. He is also an angel investor and advisor to multiple biotech companies. Prior to Eclipse Bio, Dr. Chu was founding CEO of Eclipse Therapeutics, a Biogen spin-out developing cancer stem cell antibodies. After Eclipse Therapeutics was acquired by Bionomics Limited, Dr. Chu led Bionomics’ US operations and successful Phase I clinical trials for BNC101 antibody therapy in colon cancer.

Dr. Chu began his career as a scientist at Biogen Idec, where he led the cancer stem cells program and also worked with business development and new ventures to evaluate licensing and investment opportunities. He is a graduate of McGill University, where he majored in microbiology and immunology, and holds a Ph.D from the biomedical sciences program at UC San Diego and a masters degree from the University of Toronto.